JULIA COLANGELI: Open Payments
NPI 1659016277 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,179 in 151 payments from 17 companies in 2025. Trend: 2023 $0 · 2024 $689 · 2025 $3,179
Food & beverage: $3,095Education: $84
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $656 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 24 | $484 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $367 |
| Madrigal Pharmaceuticals | 14 | $302 |
| Janssen Biotech, Inc. | 15 | $301 |
| Daiichi Sankyo Inc. | 6 | $172 |
| Ardelyx, Inc. | 9 | $143 |
| Ipsen Biopharmaceuticals, Inc | 4 | $104 |
| Intercept Pharmaceuticals, Inc. | 5 | $102 |
| GENZYME CORPORATION | 5 | $100 |
Products named: XIFAXAN, ENTYVIO, REZDIFFRA, TREMFYA, RINVOQ, DUPIXENT, INJECTAFER, SKYRIZI.
Industry payments across PA — which companies pay providers there.
